Drugs / STX-0712
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06950034 | Mar 2025 → Dec 2026 expected | acute monocytic leukemia, chronic myelomonocytic leukemia | Solu Therapeutics, Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-27 | Solu Therapeutics, Inc | Regulatory Solu Therapeutics Granted FDA Fast Track Designation for STX-0712 for Treatment of Chronic Myelomonocytic Leukemia solutherapeutics.com ↗ |
| 2024-12-09 | Solu Therapeutics, Inc | Results Solu Therapeutics Presents Positive Preclinical Data on STX-0712 for Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia at ASH Annual Meeting solutherapeutics.com ↗
STX-0712 showed robust activity against CCR2-positive monocytes in CMML and AML patient samples |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STX-0712 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06950034 ↗ |
| Route | Intravenous | “STX-0712 is IV administered every 21 days until the patient discontinues treatment.” NCT06950034 ↗ |